Molecular markers relating to malignant progression in Grade II astrocytoma: Laboratory investigation

Journal of Neurosurgery

Volumn 110, Issue 4, 2009, Pages 709-714

  Yue, Wei Ying ^a   Yu, Su Huan ^b   Zhao, Shi Guang ^c   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Astrocytoma; Ki 67; Prognosis; TP53

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN TP 53; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; P27 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE; CLINICAL ARTICLE; DISEASE SEVERITY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MICROSURGERY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR RECURRENCE; BRAIN TUMOR; CHEMISTRY; DISEASE COURSE; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; ASTROCYTOMA; BASE SEQUENCE; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65649145111     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2008.3.JNS17459     Document Type: Article

References (15)

1. Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102:55-66, 2000
2. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M: TP53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982-987, 1993 (Pubitemid 2003748)
3. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM: p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52:674-679, 1992
4. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in TP53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595-1602, 1990 (Pubitemid 20137017)
5. Hilton DA, Penney M, Evans B, Sanders H, Love S: Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 26:472-478, 2002 (Pubitemid 34280120)
6. Ishii N, Tada M, Hamou MF, Janzer RC, Meagher-Villemure K, Wiestler OD, et al: Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 18:5870-5878, 1999 (Pubitemid 29520443)
7. Kleihues P, Cavenee WK (ed): Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press, 2000
8. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, et al: Analysis of TP53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87:225-232, 1994 (Pubitemid 24051538)
9. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M: MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 57:931-936, 1998 (Pubitemid 28478003)
10. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ: Prognostic impact of TP53 mutations and TP53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117-1124, 2002 (Pubitemid 34517648)
11. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al: Expression of TP53 and prognosis in children with malignant gliomas. N Engl J Med 346:420-427, 2002 (Pubitemid 34437697)
12. Sarkar C, Ralte AM, Sharma MC, Mehta VS: Recurrent astrocytic tumours-a study of TP53 immunoreactivity and malignant progression. Br J Neurosurg 16:335-342, 2002 (Pubitemid 35178577)
13. Stander M, Peraud A, Leroch B, Kreth FW: Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101:1028-1035, 2004 (Pubitemid 39100437)
14. Torp SH, Alsaker M: Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 198:261-265, 2002
15. Watanabe K, Sato K, Biernat W, Tachibana O, Von Ammon K, Ogata N, et al: Incidence and timing of TP53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530, 1997 (Pubitemid 27211828)